Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | AGXT | P21549 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8083245 | 0.89 | PTGES (0.42) | TSHRPPARGSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6028474 | 0.86 | CETP (0.45) | CETP | |
| SCHEMBL455196 | 0.84 | TSHR (0.44) | TSHRIDO1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6098576 | 0.81 | SLC1A3 (0.42) | TSHRIDO1PPARGPPARASLC1A3 | |
| SCHEMBL2640220 | 0.80 | TSHR (0.44) | TSHRIDO1PPARGPPARASLC1A3 | |
| SCHEMBL13672306 | 0.80 | TSHR (0.44) | TSHRIDO1PPARGPPARASLC1A3 | |
| SCHEMBL28317714 | 0.79 | TSHR (0.36) | TSHRIDO1PPARGPPARASLC1A3 | |
| SCHEMBL10245222 | 0.78 | TSHR (0.43) | TSHRIDO1PPARGPPARASLC1A3 | |
| SCHEMBL7850044 | 0.78 | TSHR (0.43) | TSHRIDO1PPARGPPARASLC1A3 | |
| SCHEMBL659915 | 0.78 | TSHR (0.46) | TSHRIDO1PPARGPPARASLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3439703-A1 | NUCLEIC ACID LINKED TO A TRIVALENT GLYCOCONJUGATE | Silence Therapeutics GmbH (DE) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017174657-A1 | NUCLEIC ACID LINKED TO A TRIVALENT GLYCOCONJUGATE | SILENCE THERAPEUTICS GMBH (DE) | 2017-10-12 | — | — | WO | disclosed |
| EP-3099685-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2016-12-07 | — | — | EP | disclosed |
| WO-2015113990-A1 | NOVEL DIHYDROQUINOLIZINONES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-08-06 | — | — | WO | disclosed |
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070190523-A1 | Method and compositions for identifying anti-hiv therapeutic compounds | GILEAD SCIENCES, INC. | 2007-08-16 | — | — | US | disclosed |
| EP-1575486-A4 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES INC (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
| EP-1711617-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTICS COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-7119203-B2 | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1094805-A1 | SUBSTITUTED OXYGEN ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2001-05-02 | — | — | EP | disclosed |
| EP-1083919-A1 | NOVEL ANTIVIRAL COMPOUNDS | Advanced Medicine, Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-1054676-A1 | COMBINATION PREPARATION OF ESTROGEN AND ANTI-ESTROGEN | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-11-29 | — | — | EP | disclosed |
| EP-1042355-A1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999064047-A9 | NOVEL ANTIVIRAL COMPOUNDS | ADVANCED MEDICINE INC (US) | 2000-03-16 | — | — | WO | disclosed |
| WO-2000001381-A1 | SUBSTITUTED OXYGEN ALICYCLIC COMPOUNDS, INCLUDING METHODS FOR SYNTHESIS THEREOF | LEUKOSITE, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| WO-1999064047-A1 | NOVEL ANTIVIRAL COMPOUNDS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999042109-A1 | COMBINATION PREPARATION OF ESTROGEN AND ANTI-ESTROGEN | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-08-26 | — | — | WO | disclosed |
| WO-1999033855-A1 | 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-07-08 | — | — | WO | disclosed |
| EP-0215401-A2 | Method and composition for determining glycosylated hemoglobin as well as compounds suited therefor and methods for their preparation | Roche Diagnostics GmbH (DE) | 1987-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | TSHR 4782/4885IDO1 2558/4885PPARG 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.